在现实生活中,CYP2C19基因定型可以提高抗血小板治疗的疗效吗? 最近的进展是最近的进步
Udaya S Tantry1, Sahib Singh1, Lekshmi Narayan Raghavakurup1
1Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore and Lifebridge Health System, Baltimore, Maryland, United States.
对CYP2C19功能丧失等位基因的基因检测对于服用克洛皮多格雷尔的患者至关重要. 鉴定载体可确保选择适当的P2Y12抑制剂,提高治疗疗效,降低血栓形成风险.
科学领域:
- 药物基因组学 药物基因组学
- 心血管医学 心血管医学
- 药物新陈代谢 药物新陈代谢
背景情况:
- 广泛使用的P2Y12抑制剂克洛皮多格雷尔,由于CYP2C19代谢,患者反应变化.
- CYP2C19功能丧失 (LoF) 基因组降低了克洛皮多格雷尔的疗效,增加了血栓事件的风险.
研究的目的:
- 为了突出CYP2C19基因定型在克洛皮多格雷尔治疗中的临床意义.
- 倡导基于药物遗传特征的个性化P2Y12抑制剂选择.
主要方法:
- 临床试验和FDA关于克洛皮多格雷尔和CYP2C19基因型的警告的审查.
- 分析了替代P2Y12抑制剂 (普拉苏格勒/蒂卡格勒勒) 的优缺点.
主要成果:
- 患有CYP2C19LoF等位基因的患者经历了克洛皮多格雷尔的血小板抑制降低和更高的血栓形成风险.
- 替代P2Y12抑制剂提供更大的抗胰岛素益处,但会增加出血和成本的风险.
结论:
- 对CYP2C19LoF等位基因的基因定型得到了当前证据的强有力的支持,这些证据是针对被考虑接受克洛皮多格雷尔的患者.
- 医生应该利用基因测试来指导药理学上可预测的P2Y12抑制剂的选择,优化患者的治疗结果.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Time Course of Drug Effect
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...


